In this study, we provide evidence that circulating levels of CXCL1, CXCL10 and CXCL13 are distinctly altered in patients with BTC and that serum CXCL13 levels, in particular, represent a promising candidate to predict outcomes following tumor resection. The gene discussed is CXCL10; the disease is neoplasm.